29 January 2024
29 January 2024
Merck (MSD)'s treatment improved overall survival by 38% in renal cell carcinoma patients versus placebo.
The UK Government funds a new network to enhance dementia research and treatment.
Onward’s non-invasive neuromodulation therapy, which is FDA breakthrough device designated, has shown positive results in a pivotal trial.
The study examined 977 adults from sites across four US states and found that the use of a hearing aid with patients at risk of cognitive decline slowed loss of cognitive abilities.
The study will investigate the efficacy of NTI164 in paediatric patients with spastic diplegia cerebral palsy (spastic CP).
Dhillon partnered with professor Tim Price in Australia for the past four years for developing the vaccine.
Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.
The Phase III trial of atacicept in Berger’s disease is ongoing with enrolment due to be completed by the end of 2024.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
